These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Patient and disease characteristics of type-2 diabetes patients with or without chronic kidney disease: an analysis of the German DPV and DIVE databases. Bramlage P; Lanzinger S; van Mark G; Hess E; Fahrner S; Heyer CHJ; Friebe M; Seufert J; Danne T; Holl RW Cardiovasc Diabetol; 2019 Mar; 18(1):33. PubMed ID: 30878037 [TBL] [Abstract][Full Text] [Related]
3. Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: an emerging paradigm in diabetic nephropathy: a systematic review. Mavrakanas TA; Gariani K; Martin PY Eur J Intern Med; 2014 Feb; 25(2):173-6. PubMed ID: 24315413 [TBL] [Abstract][Full Text] [Related]
4. Eicosapentaenoic and Docosahexaenoic Acids Attenuate Progression of Albuminuria in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease. Elajami TK; Alfaddagh A; Lakshminarayan D; Soliman M; Chandnani M; Welty FK J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28710178 [TBL] [Abstract][Full Text] [Related]
5. Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy. Ruilope LM; Agarwal R; Chan JC; Cooper ME; Gansevoort RT; Haller H; Remuzzi G; Rossing P; Schmieder RE; Nowack C; Ferreira AC; Pieper A; Kimmeskamp-Kirschbaum N; Bakris GL Am J Nephrol; 2014; 40(6):572-81. PubMed ID: 25591469 [TBL] [Abstract][Full Text] [Related]
6. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure]. Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154 [TBL] [Abstract][Full Text] [Related]
8. Probucol in Albuminuric Type 2 Diabetes Mellitus Patients on Renin-Angiotensin System Blockade: A 16-Week, Randomized, Double-Blind, Placebo-Controlled Trial. Jin SM; Han KA; Yu JM; Sohn TS; Choi SH; Chung CH; Park IeB; Rhee EJ; Baik SH; Park TS; Lee IK; Ko SH; Hwang YC; Cha BS; Lee HW; Nam MS; Lee MK Arterioscler Thromb Vasc Biol; 2016 Oct; 36(10):2108-14. PubMed ID: 27493100 [TBL] [Abstract][Full Text] [Related]
9. Renoprotective effects of canagliflozin, a sodium glucose cotransporter 2 inhibitor, in type 2 diabetes patients with chronic kidney disease: A randomized open-label prospective trial. Takashima H; Yoshida Y; Nagura C; Furukawa T; Tei R; Maruyama T; Maruyama N; Abe M Diab Vasc Dis Res; 2018 Sep; 15(5):469-472. PubMed ID: 29923427 [TBL] [Abstract][Full Text] [Related]
10. Diabetic nephropathy: renoprotective effects of pentoxifylline in the PREDIAN trial. He T; Cooper ME Nat Rev Nephrol; 2014 Oct; 10(10):547-8. PubMed ID: 25201141 [No Abstract] [Full Text] [Related]
11. [Prediction, screening and treatment of renal complications of diabetes]. Marre M; Larger E Rev Prat; 2001 Oct; 51(16):1769-75. PubMed ID: 11795120 [TBL] [Abstract][Full Text] [Related]
12. Transforming the Care of Patients with Diabetic Kidney Disease. Brosius FC; Cherney D; Gee PO; Harris RC; Kliger AS; Tuttle KR; Quaggin SE; Clin J Am Soc Nephrol; 2021 Oct; 16(10):1590-1600. PubMed ID: 34103350 [TBL] [Abstract][Full Text] [Related]
15. [Novel diagnostic and therapeutic procedures in diabetic nephropathy]. Pont'uch P Vnitr Lek; 2015 Dec; 61(12 Suppl 5):5S57-62. PubMed ID: 27124974 [TBL] [Abstract][Full Text] [Related]
16. Quality of care in patients with diabetic kidney disease in Asia: The Joint Asia Diabetes Evaluation (JADE) Registry. Luk AO; Li X; Zhang Y; Guo X; Jia W; Li W; Weng J; Yang W; Chan WB; Ozaki R; Tsang CC; Mukhopadhyay M; Ojha AK; Hong EG; Yoon KH; Sobrepena L; Toledo RM; Duran M; Sheu W; Q Do T; Nguyen TK; Ma RC; Kong AP; Chow CC; Tong PC; So WY; Chan JC; Diabet Med; 2016 Sep; 33(9):1230-9. PubMed ID: 26511783 [TBL] [Abstract][Full Text] [Related]